← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Beam Therapeutics Inc. (BEAM) 10-Year Financial Performance & Capital Metrics

BEAM •
HealthcareBiotechnologyRNA and Genome Editing Developers
AboutBeam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.Show more
  • Revenue $140M +120.0%
  • EBITDA -$377M +4.1%
  • Net Income -$80M +78.8%
  • EPS (Diluted) -0.81 +82.3%
  • Gross Margin 84.05% +117.6%
  • EBITDA Margin -270.04% +56.4%
  • Operating Margin -274.57% +58.0%
  • Net Margin -57.24% +90.3%
  • ROE -8.11% +81.5%
  • ROIC -33.65% +28.1%
  • Debt/Equity 0.12 -43.4%
  • Interest Coverage -8.77
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 82 (top 18%)
  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Strong 5Y sales CAGR of 466.3%

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Shares diluted 20.2% in last year
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y466.27%
3Y31.88%
TTM120.01%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM78.77%

EPS CAGR

10Y-
5Y-
3Y-
TTM77.95%

ROCE

10Y Avg-42.74%
5Y Avg-32.71%
3Y Avg-28.78%
Latest-33.28%

Peer Comparison

RNA and Genome Editing Developers
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
ALNYAlnylam Pharmaceuticals, Inc.44.07B332.92142.8865.19%8.45%39.76%1.06%3.76
SLXNWSilexion Therapeutics Ltd.63.6M0.030.00-132.54%
EDITEditas Medicine, Inc.205.18M2.20-0.76-58.64%-430.84%-14.85%0.26
SGMOSangamo Therapeutics, Inc.92.01M0.43-0.88-67.2%-331.28%-17.44%1.34
CAMPCAMP4 Therapeutics Corporation210.49M4.49-1.6986.29%-14.04%-133.54%0.14
SLNSilence Therapeutics plc256.95M5.44-1.7170.47%-252.16%-84.61%0.00
PEPGPepGen Inc.202.89M6.22-2.18-57.35%0.16
ARCTArcturus Therapeutics Holdings Inc.224.14M8.23-2.74-12.27%-72.48%-29.71%0.12

Compare BEAM vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs ALNY

Compare head-to-head with Alnylam Pharmaceuticals, Inc.

vs IONS

Compare head-to-head with Ionis Pharmaceuticals, Inc.

Compare Top 5

vs ALNY, IONS, ARWR, CRSP

Profit & Loss

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Sales/Revenue+0018K24K51.84M60.92M377.71M63.52M139.74M
Revenue Growth %---33.33%215916.67%17.51%520.01%-83.18%120.01%
Cost of Goods Sold+033.87M54.62M103.18M232.13M311.59M0367.56M22.29M
COGS % of Revenue--303438.89%429912.5%447.75%511.48%-578.67%15.95%
Gross Profit+0-33.87M-54.6M-103.16M-180.29M-250.67M377.71M-304.04M117.45M
Gross Margin %---303338.89%-429812.5%-347.75%-411.48%100%-478.67%84.05%
Gross Profit Growth %---61.19%-88.93%-74.78%-39.04%250.68%-180.5%138.63%
Operating Expenses+8.6M11.87M20.55M29.6M212.18M87.81M554.19M111.53M501.14M
OpEx % of Revenue--114183.33%123354.16%409.26%144.13%146.73%175.58%358.62%
Selling, General & Admin2.2M11.87M20.55M29.61M57.22M87.81M116.81M111.53M113.82M
SG&A % of Revenue--114183.33%123354.17%110.37%144.13%30.93%175.58%81.45%
Research & Development5.86M33.87M54.62M103.18M387.09M311.59M437.38M367.56M409.62M
R&D % of Revenue--303438.89%429912.5%746.64%511.48%115.8%578.67%293.12%
Other Operating Expenses0-33.87M-54.62M-103.18M-232.13M-311.59M0-367.56M-22.29M
Operating Income+-8.6M-45.74M-75.15M-132.76M-392.46M-338.48M-176.49M-415.57M-383.69M
Operating Margin %---417522.22%-553166.66%-757.01%-555.61%-46.73%-654.25%-274.57%
Operating Income Growth %--432.1%-64.3%-76.65%-195.62%13.76%47.86%-135.47%7.67%
EBITDA+-8.58M-45.09M-71.65M-128.03M-385.01M-324.33M-146.95M-393.64M-377.36M
EBITDA Margin %---398061.11%-533437.5%-742.64%-532.39%-38.91%-619.73%-270.04%
EBITDA Growth %--425.27%-58.9%-78.68%-200.73%15.76%54.69%-167.87%4.14%
D&A (Non-Cash Add-back)12K650K3.5M4.73M7.45M14.15M29.53M21.93M6.34M
EBIT-8.6M-45.74M-75.15M-132.76M-237.51M-338.48M-176.49M-415.57M-36.26M
Net Interest Income+002.3M1.57M00049.09M-43.73M
Interest Income0292K2.49M1.57M00049.09M0
Interest Expense00187K0000043.73M
Other Income/Expense-133.09K-71M-3.17M-61.83M21.83M52.8M45.32M38.87M303.7M
Pretax Income+-8.73M-116.74M-78.33M-194.59M-370.64M-285.68M-131.16M-376.7M-79.99M
Pretax Margin %---435144.44%-810800%-714.91%-468.94%-34.73%-593.07%-57.24%
Income Tax+500K00003.41M1.37M39K0
Effective Tax Rate %100%98.73%100%100%100%101.19%101.04%100.01%100%
Net Income+-8.73M-115.26M-78.33M-194.59M-370.64M-289.09M-132.53M-376.74M-79.99M
Net Margin %---435144.44%-810800%-714.91%-474.54%-35.09%-593.13%-57.24%
Net Income Growth %--1220.32%32.04%-148.44%-90.47%22%54.16%-184.28%78.77%
Net Income (Continuing)-8.73M-116.74M-78.33M-194.59M-370.64M-289.09M-132.53M-376.74M-79.99M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)+-0.62-3.28-1.53-5.49-5.77-4.13-1.72-4.58-0.81
EPS Growth %--429.03%53.35%-258.82%-5.1%28.42%58.35%-166.28%82.31%
EPS (Basic)-0.62-3.28-1.53-5.49-5.77-4.13-1.72-4.58-0.81
Diluted Shares Outstanding12.95M35.14M51.34M46.73M64.23M70.02M77.15M82.31M98.91M
Basic Shares Outstanding12.95M35.14M51.34M46.73M64.23M70.02M77.15M82.31M98.91M
Dividend Payout Ratio---------

Balance Sheet

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Current Assets+2.04M148.28M94.54M308.32M1.27B1.09B1.21B878.15M1.27B
Cash & Short-Term Investments1.9M146.44M91.85M299.67M965.65M1.08B1.19B850.74M1.25B
Cash Only1.9M146.44M37.22M162.17M559.99M232.77M435.89M281.97M294.94M
Short-Term Investments0054.63M137.5M405.65M845.37M753.98M568.77M950.27M
Accounts Receivable0000300M0000
Days Sales Outstanding----2.11K----
Inventory000000000
Days Inventory Outstanding---------
Other Current Assets0000014.76M21.17M27.41M0
Total Non-Current Assets+365K18.74M61.55M143.36M201.45M248.82M248.67M225.68M212.49M
Property, Plant & Equipment335K16.94M43.25M125.37M186.98M234.13M237.81M216.28M205.18M
Fixed Asset Turnover--0.00x0.00x0.28x0.26x1.59x0.29x0.68x
Goodwill000000000
Intangible Assets000000000
Long-Term Investments30K1.49M0000006.68M
Other Non-Current Assets0300K18.31M17.98M14.47M14.69M10.87M9.4M634K
Total Assets+2.4M167.01M156.1M451.68M1.47B1.34B1.46B1.1B1.48B
Asset Turnover--0.00x0.00x0.04x0.05x0.26x0.06x0.09x
Asset Growth %-6853.04%-6.53%189.35%226.44%-9%8.79%-24.38%34.19%
Total Current Liabilities+6.57M25.59M29.14M102.34M213.44M223.59M205.56M182.07M96.94M
Accounts Payable726K7.35M7.85M6.31M7.47M9.03M1.62M3.87M10.23M
Days Payables Outstanding-79.2152.4322.3411.7510.58-3.84167.5
Short-Term Debt1.01M01.3M2.12M2.29M00014.36M
Deferred Revenue (Current)-1.01M0024K86.27M135.97M68.71M108.86M6.66M
Other Current Liabilities4.7M16.54M12.56M83.02M60.83M49.68M100.69M19.74M51.32M
Current Ratio0.31x5.79x3.24x3.01x5.96x4.89x5.89x4.82x13.09x
Quick Ratio0.31x5.79x3.24x3.01x5.96x4.89x5.89x4.82x13.09x
Cash Conversion Cycle---------
Total Non-Current Liabilities+20K7.4M26.02M103.78M434.28M384.64M272.82M188.21M145.88M
Long-Term Debt004.41M5.29M3.01M000139.76M
Capital Lease Obligations0021.19M96.01M134.81M168.63M159.91M147.96M139.76M
Deferred Tax Liabilities000000000
Other Non-Current Liabilities20K7.4M418K2.08M34.16M13.84M3.02M7.04M-133.63M
Total Liabilities6.58M32.98M55.15M206.12M647.72M608.24M478.38M370.28M242.82M
Total Debt+1.01M031.24M107.64M147.64M179M172.69M161.43M154.12M
Net Debt-891K-146.44M-5.98M-54.53M-412.35M-53.76M-263.21M-120.54M-140.82M
Debt / Equity--0.31x0.44x0.18x0.24x0.18x0.22x0.12x
Debt / EBITDA---------
Net Debt / EBITDA---------
Interest Coverage---401.89x------8.77x
Total Equity+-4.18M134.03M100.94M245.56M826.74M733.47M981.33M733.54M1.24B
Equity Growth %-3304.11%-24.68%143.26%236.67%-11.28%33.79%-25.25%68.82%
Book Value per Share-0.323.811.975.2512.8710.4812.728.9112.52
Total Shareholders' Equity-4.18M134.03M100.94M245.56M826.74M733.47M981.33M733.54M1.24B
Common Stock5K56K73K573K684K712K816K836K1.02M
Retained Earnings-9.46M-124.72M-203.04M-397.64M-768.27M-1.06B-1.19B-1.57B-1.64B
Treasury Stock000000000
Accumulated OCI-11K-661K16K-9K-50K-2.43M604K679K1.11M
Minority Interest000000000

Cash Flow

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Cash from Operations+-2.71M-20.3M-72M-95.74M-66.27M22.53M-149.19M-347.25M-345.1M
Operating CF Margin %---400016.67%-398920.83%-127.82%36.98%-39.5%-546.69%-246.95%
Operating CF Growth %--649.83%-254.73%-32.97%30.78%133.99%-762.29%-132.75%0.62%
Net Income-8M-116.74M-78.33M-194.59M-370.64M-289.09M-132.53M-376.74M-79.99M
Depreciation & Amortization11K650K3.5M4.74M7.45M14.15M20.01M21.93M22.29M
Stock-Based Compensation198K7M7.03M15.38M43.57M84.32M98.65M120.66M94.24M
Deferred Taxes500K11.75M063.52M00000
Other Non-Cash Items3.85M66.96M6.5M9.87M142.09M-38.48M-18.87M-2.87M-250.63M
Working Capital Changes740K10.07M-10.71M5.35M111.25M251.63M-116.45M-110.22M-131.02M
Change in Receivables0000-300M300M000
Change in Inventory00000-300M000
Change in Payables726K2.44M4.09M60K818K2.37M-7.58M1.81M6.04M
Cash from Investing+-346K-13.42M-66.66M-100.12M-294.14M-461.34M71.84M185.01M-121.44M
Capital Expenditures-346K-13.12M-12.52M-16.36M-46.81M-48.95M-33.73M-8.95M-14.95M
CapEx % of Revenue--69544.44%68154.17%90.29%80.35%8.93%14.08%10.7%
Acquisitions00083.77M620K412.38M00-78K
Investments---------
Other Investing0-300K0-83.77M0-412.38M00254.75M
Cash from Financing+4.98M179.73M41.28M322.32M756.14M111.59M276.45M7.74M478.05M
Debt Issued (Net)005.71M1.7M-2.12M-2.29M-2.25M-485K0
Equity Issued (Net)1000K1000K1000K1000K1000K1000K1000K1000K1000K
Dividends Paid000000000
Share Repurchases000000000
Other Financing010K-2.34M1.1M810K5.62M8.53M00
Net Change in Cash1.93M146M-97.38M126.46M395.73M-327.22M199.09M-154.5M11.51M
Free Cash Flow+-3.05M-33.42M-84.52M-112.1M-113.08M-26.42M-182.93M-356.19M-360.05M
FCF Margin %---469561.11%-467075%-218.11%-43.37%-48.43%-560.77%-257.65%
FCF Growth %--994.73%-152.89%-32.63%-0.88%76.63%-592.28%-94.72%-1.08%
FCF per Share-0.24-0.95-1.65-2.40-1.76-0.38-2.37-4.33-3.64
FCF Conversion (FCF/Net Income)0.31x0.18x0.92x0.49x0.18x-0.08x1.13x0.92x4.31x
Interest Paid00187K0567K0000
Taxes Paid000000000

Key Ratios

Metric201720182019202020212022202320242025
Return on Equity (ROE)--177.53%-66.67%-112.32%-69.13%-37.06%-15.46%-43.94%-8.11%
Return on Invested Capital (ROIC)---136.57%-69.63%-97.24%-46.41%-18.94%-46.83%-33.65%
Gross Margin---303338.89%-429812.5%-347.75%-411.48%100%-478.67%84.05%
Net Margin---435144.44%-810800%-714.91%-474.54%-35.09%-593.13%-57.24%
Debt / Equity--0.31x0.44x0.18x0.24x0.18x0.22x0.12x
Interest Coverage---401.89x------8.77x
FCF Conversion0.31x0.18x0.92x0.49x0.18x-0.08x1.13x0.92x4.31x
Revenue Growth---33.33%215916.67%17.51%520.01%-83.18%120.01%

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.